Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?
作者信息
Greally Megan, Ku Geoffrey Y
机构信息
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
出版信息
J Thorac Dis. 2018 Dec;10(12):6407-6411. doi: 10.21037/jtd.2018.12.01.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?免疫检查点抑制剂在食管胃腺癌中的应用：结果是否证实了其大肆宣传的效果？
J Thorac Dis. 2018 Dec;10(12):6407-6411. doi: 10.21037/jtd.2018.12.01.
2
The Current Status of Immunotherapies in Esophagogastric Cancer.食管癌和胃癌免疫疗法的现状
Surg Oncol Clin N Am. 2017 Apr;26(2):277-292. doi: 10.1016/j.soc.2016.10.012.
3
The Current Status of Immunotherapies in Esophagogastric Cancer.免疫治疗在食管胃结合部癌中的现状。
Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007.
4
Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction.使用 PET/MRI 对新辅助治疗进行早期反应评估，预测食管胃结合部腺癌患者的可切除性。
Abdom Radiol (NY). 2019 Mar;44(3):836-844. doi: 10.1007/s00261-018-1841-4.
5
Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients.日本患者外科切除的食管胃结合部腺癌及微卫星不稳定性状态的近期发病趋势。
Digestion. 2019;99(1):6-13. doi: 10.1159/000494406. Epub 2018 Dec 14.
6
Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.食管癌和胃癌的全身治疗：免疫检查点抑制
Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03.
7
Advances in the treatment of gastric cancer.胃癌治疗的进展
Curr Opin Gastroenterol. 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395.
8
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.免疫疗法治疗内分泌恶性肿瘤：免疫检查点抑制剂引领潮流。
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281. doi: 10.1530/ERC-17-0222. Epub 2017 Sep 11.
9
Antiangiogenic Therapy in Gastroesophageal Cancer.食管癌的抗血管生成治疗
Hematol Oncol Clin North Am. 2017 Jun;31(3):499-510. doi: 10.1016/j.hoc.2017.01.008. Epub 2017 Mar 22.
10
Epidemiology of adenocarcinoma of the esophagogastric junction.食管胃交界腺癌的流行病学
Surg Oncol Clin N Am. 2006 Oct;15(4):687-96. doi: 10.1016/j.soc.2006.07.014.
引用本文的文献
1
Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.新辅助 PD-1 联合化疗治疗局部晚期食管鳞癌。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241231610. doi: 10.1177/15330338241231610.
2
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials.PD-1和PD-L1免疫检查点抑制剂治疗食管癌的当前证据：一项更新的荟萃分析及正在进行的临床试验综述
Ther Adv Med Oncol. 2024 Jan 9;16:17588359231221339. doi: 10.1177/17588359231221339. eCollection 2024.
3
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials.PD-1/PD-L1抑制剂在晚期胃食管癌患者中的疗效：基于随机对照试验的最新荟萃分析
Front Pharmacol. 2022 Oct 25;13:1009254. doi: 10.3389/fphar.2022.1009254. eCollection 2022.
4
The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis.靶向程序性死亡受体1（PD-1）抗体治疗晚期食管癌的疗效与安全性：一项系统评价与荟萃分析
Transl Oncol. 2021 Jun;14(6):101083. doi: 10.1016/j.tranon.2021.101083. Epub 2021 Mar 27.
5
Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.基于下一代测序的食管鳞癌基因突变。
Chin Med J (Engl). 2021 Feb 25;134(6):708-715. doi: 10.1097/CM9.0000000000001411.
6
Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma.中国食管鳞状细胞癌患者的突变特征及潜在预后生物标志物
Onco Targets Ther. 2020 Dec 14;13:12797-12809. doi: 10.2147/OTT.S275688. eCollection 2020.
7
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.食管鳞状细胞癌中的免疫检查点抑制剂：进展与机遇
Onco Targets Ther. 2019 Jul 29;12:6023-6032. doi: 10.2147/OTT.S214579. eCollection 2019.
本文引用的文献
1
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.CheckMate-032 研究：纳武利尤单抗和纳武利尤单抗联合伊匹单抗治疗转移性胃食管交界部癌患者的疗效和安全性。
J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.
2
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.avelumab 对比医师选择的化疗作为晚期胃癌或胃食管结合部癌三线治疗的 III 期随机试验：JAVELIN Gastric 300 的主要分析结果
Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
3
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.PD-1 抑制治疗转移性胃癌的临床反应的全面分子特征分析。
Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.
4
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
5
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负担与纳武利尤单抗单药治疗及联合伊匹单抗治疗小细胞肺癌的疗效。
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.
6
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
7
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
8
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
9
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
10
Comprehensive molecular characterization of gastric adenocarcinoma.胃腺癌的全面分子特征分析。
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
Zotero 插件